Introduction: Congestive Heart Failure (CHF) is a disorder in which the heart is unable to supply enough blood for body tissues. Since heart is an adaptable organ, it overcomes this condition by going under remodeling process. Considering cardiac myocytes are capable of proliferation after MI, stimulation of neovascularization as well as their regeneration might serve as a novel target in cardiac remodeling prevention and CHF treatment. Granulocyte Colony-Stimulating Factor (G-CSF), is a hematopoietic cytokine that promotes proliferation and differentiation of neutrophils and is involved in cardiac repair after MI. So far, this is the first review to focus on GCSF as a novel treatment for heart failure.
Methods: We conducted a search of some databases such as PubMed for articles and reviews published between 2003 and 2017, with different keywords including “G-CSF”, “congestive heart failure”, “new therapies for CHF”, “filgrastim”, “in vivo study”.
Results: GCSF exerts its beneficial effects on cardiac repair through either stem cell mobilization or direct angiogenesis promotion. All of which are capable of promoting cardiac cell repair.
Conclusion: GCSF is a promising target in CHF-therapy by means of cardiac repair and remodeling prevention through multiple mechanisms, which are effective enough to be used in clinical practice.
Keywords: In vivo study, new therapies for CHF, filgrastim, congestive heart failure, G-CSF, prevention.
Use of STAT1 Inhibitors in the Treatment of Brain I/R Injury and Neurodegenerative Diseases
Central Nervous System Agents in Medicinal Chemistry Lactic Acid Bacteria with Concomitant IL-17, IL-23 and TNFα- Binding Ability for the Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Biotechnology HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) DNA Mismatch Repair Deficiency, Resistance to Cancer Chemotherapy and the Development of Hypersensitive Agents
Current Topics in Medicinal Chemistry HRV Signaling in Airway Epithelial Cells Is Regulated by ITAM-Mediated Recruitment and Activation of Syk
Protein & Peptide Letters Consequences of Iron Accumulation in Microglia and its Implications in Neuropathological Conditions
CNS & Neurological Disorders - Drug Targets Renal COX-2, Cytokines and 20-HETE: Tubular and Vascular Mechanisms
Current Pharmaceutical Design Targeting Inflammation in Primary Cardiovascular Prevention
Current Pharmaceutical Design Gamma Linolenic Acid: An Antiinflammatory Omega-6 Fatty Acid
Current Pharmaceutical Biotechnology Metabolic Syndrome and Adipose Tissue: New Clinical Aspects and Therapeutic Targets
Current Pharmaceutical Design Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Novel Carriers for Controlled Site Specific Delivery of Anti-Inflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry VEGF, Angiopoietin-1 and -2 in Bronchial Asthma: New Molecular Targets in Airway Angiogenesis and Microvascular Remodeling
Recent Patents on Inflammation & Allergy Drug Discovery Mn-SOD and Chronic Inflammation of Gastric Mucosa
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Implication of Heat Shock Protein 90 (HSP90) in Tumor Angiogenesis: A Molecular Target for Anti-Angiogenic Therapy?
Current Cancer Drug Targets Role of Interferons in Chronic Hepatitis C Infection
Current Drug Targets Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism The Delicate Balance between the Good and the Bad IL-1 Proinflammatory Effects in Endometriosis
Current Medicinal Chemistry Effect of Hypoxia on Cytochrome P450 Activity and Expression
Current Drug Metabolism Local Delivery of Therapeutics for Percutaneous Coronary Intervention
Current Drug Delivery